Marshall Wace, LLP Bicycle Therapeutics PLC Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 330,258 shares of BCYC stock, worth $4.99 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

330,258

Previous 88,987 271.13%

Holding current value

$4.99 Million

Previous $1.8 Million 315.88%

% of portfolio

0.01%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.58 - $27.24 $4.72 Million - $6.57 Million	241,271 Added 271.13%	330,258 $7.49 Million
Q2 2024 Aug 14, 2024	BUY	$20.02 - $24.69 $1.78 Million - $2.2 Million	88,987 New	88,987 $1.8 Million
Q2 2023 Aug 14, 2023	SELL	$18.95 - $28.67 $1.28 Million - $1.93 Million	-67,378 Reduced 87.9%	9,271 $236,000
Q1 2023 May 15, 2023	BUY	$20.02 - $31.37 $1.35 Million - $2.11 Million	67,378 Added 726.76%	76,649 $1.63 Million
Q3 2022 Nov 14, 2022	SELL	$17.49 - $28.44 $1.24 Million - $2.02 Million	-70,852 Reduced 88.43%	9,271 $216,000
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $900,076 - $3.27 Million	69,504 Added 654.52%	80,123 $1.34 Million
Q1 2022 May 16, 2022	SELL	$40.12 - $59.5 $1.6 Million - $2.37 Million	-39,779 Reduced 78.93%	10,619 $466,000
Q4 2021 Feb 14, 2022	BUY	$41.7 - $61.14 $1.78 Million - $2.61 Million	42,704 Added 555.03%	50,398 $3.07 Million
Q2 2021 Aug 13, 2021	SELL	$27.0 - $32.28 $384,021 - $459,118	-14,223 Reduced 64.89%	7,694 $234,000
Q1 2021 May 17, 2021	BUY	$19.12 - $30.25 $419,053 - $662,989	21,917 New	21,917 $655,000

Others Institutions Holding BCYC

# of Institutions

112

Shares Held

41.2M

Call Options Held

39.6K

Put Options Held

24.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $449M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Bicycle Therapeutics PLC Transaction History